OncoNano COO Brent Sorrells [Composite image; source: OncoNano Medicine/DI Studio]

Dallas cancer therapeutic company OncoNano Medicine has named Brent Sorrells as its new chief operating officer.

With more than two decades of experience in product development, strategic operations, and commercial execution across the biotechnology industry, Sorrells will help drive OncoNano’s next phase of growth and operational excellence, the company said.

“Brent joins OncoNano at a pivotal inflection point as we advance our first polymer drug conjugate from our ON-BOARD micelle platform into IND-enabling studies and continue development of ONM-501, our dual-acting STING agonist,” CEO Kartik Krishnan, M.D., said in a statement. “Brent’s extensive operational and leadership experience will be instrumental as we advance our strategic priorities and continue to execute on key growth milestones.”

OncoNano’s name—a fusion of oncology and nanotechnology—communicates its core mission to develop cancer treatments using nanotechnology. Founded in 2014 and now based at Dallas’s Pegasus Park, the clinical-stage company is pioneering the use of nanotech in the long-standing battle against cancer.

Sorrells most recently served as VP of product development and strategy at Allakos, Inc., until its acquisition in May 2025. During his time at Allakos, he held various leadership roles in clinical operations. Sorrells previously served in leadership within the clinical team at Fort Worth’s ZS Pharma, which was acquired by AstraZeneca in 2015 for $2.7 billion. He has also worked for and served as board chair at TechFW, the Fort Worth-based nonprofit business incubator for tech startups.

“OncoNano’s vision to redefine how cancer is treated through targeted delivery of medicines to improve their therapeutic index is truly compelling,” said Sorrells. “The science, the team, and the opportunity to make a real difference for patients make this an incredibly exciting time to come on board.”

OncoNano Medicine is a clinical-stage biotechnology company aiming to transform cancer therapeutics with its proprietary nanotechnology platform. OncoNano’s polymeric micelle platform is designed to leverage a universal tumor target, namely pH, to precisely deliver anti-cancer payloads to the tumor microenvironment.

Don’t miss what’s next. Subscribe to Dallas Innovates.

Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.

 

R E A D   N E X T

  • North Texas has plenty to see, hear, and watch. Here are our editors’ picks. Plus, you’ll find more selections to “save the date.”

  • Social entrepreneur Byron Sanders, a former nonprofit exec, is CEO of Arete Health, launched in January 2025. [Photo: Michael Samples]

    Creatives Care Dallas brings virtual care, behavioral health, 2,000+ medications with zero copay, and more to Dallas County’s gig workers. The community initiative is powered by Arete Health Shield in partnership with the Dallas Music Office.

  • nominate by sept 12, 2025, for The Innovation Awards 2026, presented by D CEO and Dallas Innovates

    D CEO and Dallas Innovates have expanded The Innovation Awards 2026 with more individual and company categories this year. Now is your chance to be part of the region’s defining recognition for innovators.

  • The board cited Catherine Cuellar's cross-sector experience and community focus in selecting her to succeed CEO Tony Fleo after more than a decade of his leadership.

    A familiar figure in Dallas arts, civic innovation, and public service, Cuellar will succeed longtime CEO Tony Fleo following a months-long search as Social Venture Partners Dallas plans its next 25 years.

  • Data scientist Anmolika Singh put Dallas on the global AI Tinkerers map. At the first meetup, more than 30 pros—founders to Fortune 500 technologists—showed up to trade ideas, projects, and solutions.